Core Viewpoint - InnoCare (Suzhou) Technology Co., Ltd. plans to issue 20,700,000 new H-shares to enhance its financial strength and support business expansion, with a share price set at HKD 75.58, representing a discount of approximately 7.88% from the last trading price of HKD 82.05 [1][3]. Summary by Sections Share Placement Details - The placement agent aims to secure subscriptions from at least six independent professional and institutional investors [3]. - The new shares represent about 4.1% of the existing issued H-shares and approximately 2.31% of the total issued shares, with post-placement proportions of about 3.94% and 2.26% respectively [3]. Use of Proceeds - The estimated net proceeds from the placement are approximately HKD 1.55 billion, allocated as follows: - Capacity expansion and product upgrades: approximately HKD 482.26 million (31%) to meet the growing demand for GaN power devices and enhance product competitiveness [5]. - Debt repayment: approximately HKD 376.24 million (24%) to optimize capital structure and reduce financial burden [6]. - Working capital and general corporate purposes: approximately HKD 691.93 million (45%), which includes human resources expenses, payments to suppliers, and potential domestic and foreign investments [7]. Share Capital Changes - Post-placement, the company's registered capital and total shares will change to RMB 915,100,653 and 915,100,653 shares respectively [7]. - The company will apply for the listing and trading of the new shares on the Stock Exchange of Hong Kong and will comply with the filing rules of the China Securities Regulatory Commission [7].

Core Viewpoint - InnoScience (Suzhou) Technology Co., Ltd. plans to issue 20,700,000 new H-shares to enhance financial strength and support business expansion, with a share price set at HKD 75.58, representing a discount of approximately 7.88% from the last trading price [2] Financial Details - The net proceeds from the placement are expected to be approximately HKD 1.55 billion, allocated as follows: - Approximately HKD 482 million for capacity expansion and product iteration to meet the growing demand for GaN power devices [2] - Approximately HKD 376 million for debt repayment to optimize capital structure and reduce financial burden [2] - Approximately HKD 692 million for working capital and general corporate purposes, including human resources expenses and payments to suppliers [2] Share Structure - The placement shares will account for about 4.1% of the existing issued H-shares and approximately 2.31% of the total issued shares, with post-placement proportions changing to about 3.94% and 2.26% respectively [2] - The company's registered capital and total shares will be updated to RMB 915,100,653 and 915,100,653 shares respectively following the placement [2]

Core Viewpoint - InnoLux Corporation (stock code: 2577) announced a financing plan through the placement of new H-shares, aiming to raise approximately HKD 15.6 billion, with net proceeds expected to be around HKD 15.5 billion after expenses [1] Group 1: Financing Details - The company plans to issue 20,700,000 shares (approximately 2.1 million shares) at a placement price of HKD 75.58, which represents a discount of about 7.88% compared to the previous trading day's closing price of HKD 82.05 [1] - The placement price also reflects a discount of approximately 15.15% compared to the average closing price of HKD 89.08 over the past five trading days [1] - The newly issued shares will account for about 2.31% of the existing issued share capital and approximately 2.26% of the enlarged share capital upon completion [1] Group 2: Use of Proceeds - Approximately HKD 4.82 billion will be allocated for capacity expansion and product iteration upgrades [1] - Around HKD 3.76 billion is designated for repaying interest-bearing debts [1] - Approximately HKD 6.92 billion will be used for working capital and general corporate purposes [1] Group 3: Company Background - InnoLux is a company operating in the gallium nitride power device sector, with its main business activities spanning consumer electronics, automotive electronics, and data centers [1]

Core Viewpoint - InnoCare Pharma (02577) plans to issue 20.7 million new H-shares at a price of HKD 75.58 per share, representing a discount of approximately 7.88% from the closing price on October 9, 2023 [1] Summary by Categories Share Issuance - The proposed share issuance will account for approximately 3.94% of the enlarged H-share capital and about 2.26% of the total issued shares [1] Financial Details - The total expected proceeds from the share placement are approximately HKD 1.5645 billion, with net proceeds estimated at around HKD 1.5504 billion [1] Use of Proceeds - Approximately 31% of the net proceeds will be allocated for capacity expansion and continuous product upgrades - About 24% will be used to repay interest-bearing debts - Approximately 45% will be designated for working capital and general corporate purposes [1]

假设所有配售股份均获悉数配售，预计配售所得款项总额及所得款项净额分别为15.645亿港元及约 15.504亿港元。配售所得款项净额拟用于以下用途：(1)约31%的资金用于产能扩充及产品持续迭代升 级。(2)约24%的资金用于偿还有息负债。(3)约45%的资金用作营运资金及一般公司用途。 英诺赛科(02577)发布公告，于2025年10月10日，公司拟配售2070万股新H股，分别占经配发及发行配售 股份扩大后的H股及已发行股份总数的约3.94%及约2.26%。配售价每股H股75.58港元，较10月9日收市 价每股H股82.05港元折让约7.88%。 ...

配售股份分别占本公告日期已发行H股及已发行股份总数的约4.10%及约2.31%。假定所有配售股份均获 悉数配售，配售的所得款项总额及所得款项净额预计分别为15.645亿港元及约15.504亿港元。配售所得 款项净额拟用于以下用途：约31%的资金用于产能扩充及产品持续迭代升级；约24%的资金用于偿还有 息负债；及约45%的资金用作营运资金及一般公司用途。 格隆汇10月10日丨英诺赛科(02577.HK)发布公告，2025年10月10日(联交所交易时段前)，公司与配售代 理(即中信里昂及海通国际)订立配售协议，据此，配售代理已有条件及单独(而非共同或共同及单独)同 意作为公司代理尽力促使合共不少于六名承配人按照配售协议所载条款并在其条件规限下购买2070万股 新H股，配售价为每股H股75.58港元。公司将根据一般授权发行配售股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據1933年美國證券法（經修訂）登記 或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將僅以 招股章程的方式進行，該招股章程可向發行人或出售證券持有人取得，並載有發行人及管理層 的詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 InnoScience (Suzhou) Technology Holding Co., Ltd. 英 諾 賽 科（ 蘇 州 ）科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2577） 根據一般授 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 英諾賽科（蘇州）科技股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02577 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 504,841,187 | RMB | | | 1 RMB | | 504,841,187 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 504,841,187 | RMB | | | 1 RMB | | 504,841,187 | | 2. 股份分類 ...

| 半导体 | | | | | --- | --- | --- | --- | | 5993.473 ↓ -190.805 -3.09% | | | 公易中 | | : 图目 . | | | | | 最高价 6251.265 | 开盘价 6173.043 | 成交量 2270.27万 | | | 最低价 5981.270 | 昨收价 6184.278 | 成交额 13.99亿 | | | 市盈率 212.695 | 换手率 0.11% | 总市值 1.01万亿 (m) | | | 市净率 4.182 | 平均价 6116.268 | 流通值 7174.9亿 | | | 上 涨4 | 平 盘 3 | 下 跌 10 | | | 52周最高 6251.265历史最高 6251.265 | | | | | 52周最低 1607.153历史最低 665.310 | 14 | | | 消息面上，高盛上调中芯国际和华虹半导体港股目标价，称中国不断扩大的AI生态为半导体带来机 遇。将两家公司的目标价均上调至117港元，此前中芯国际和华虹半导体目标价分别为95港元和87港 元。分析师Allen Chang等人在报告中表示："随 ...

Core Viewpoint - The company, InnoCare Pharma (02577.HK), has submitted an application to the China Securities Regulatory Commission to convert 373,841,270 domestic unlisted shares into H-shares, aiming for full circulation of H-shares [1] Summary by Relevant Sections Company Actions - InnoCare Pharma has applied for the conversion of 373,841,270 domestic unlisted shares into H-shares, which will allow these shares to be traded on the Hong Kong Stock Exchange after obtaining necessary regulatory approvals [1] - The total share capital of the company is 894,400,653 shares, with H-shares totaling 504,841,187 shares, representing approximately 56.44% of the total share capital [1] Shareholder Communication - Communication with all holders of domestic unlisted shares indicates that 373,841,270 shares, or about 95.97% of the total domestic unlisted shares, support the H-share full circulation application, which accounts for approximately 41.80% of the company's total share capital [1] Post-Conversion Structure - Upon completion of the H-share full circulation, the total number of H-shares will increase to 878,682,457 shares, representing approximately 98.24% of the company's total share capital, while the number of domestic unlisted shares will decrease to 15,718,196 shares, accounting for about 1.76% of the total share capital [1]